{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T05:12:44Z","timestamp":1794460364036,"version":"4.9.1"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Primary aldosteronism (PA) is the most common form of secondary hypertension. Although hypertensive disorders seem to affect around 5\u201310% of pregnancies worldwide, literature counts less than 80 cases of PA diagnosed during the peri-partum period.\u00a0In this review we discuss about current knowledge on pathophysiology, natural history, diagnosis and treatment of PA in pregnancy.\u00a0Because of the physiologic changes in the renin\u2013angiotensin\u2013aldosterone system (RAAS) and the contraindication to both confirmatory test and subtype differentiation, diagnosis of PA during pregnancy is challenging and relies mostly on detection of low\/suppressed renin and high aldosterone levels. The course of pregnancy in patients with PA is highly variable, ranging from progesterone-induced amelioration of blood pressure (BP) control to severe and resistant hypertension with potential maternal and fetal complications. Mineralcorticoid receptor antagonists (MRA) are the recommended and most effective drugs for treatment of PA. As the anti-androgenic effect of spironolactone can potentially interfere with sexual development, their prescription is not recommended during pregnancy. On the other side, eplerenone, has proven to be safe and effective in 6 pregnant women and may be added to conventional first line drug regimen in presence of resistant hypertension or persistent hypokalemia.\u00a0Ideally, patients with unilateral forms of PA should undergo adrenalectomy prior to conception, however, when PA is diagnosed during pregnancy and medical therapy fails to adequately control hypertension or its complications, adrenalectomy can be considered during the second trimester in case of unilateral adrenal mass at MRI-scan.<\/jats:p>","DOI":"10.1007\/s11154-022-09729-6","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T01:02:31Z","timestamp":1652144551000},"page":"39-48","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Primary aldosteronism in pregnancy"],"prefix":"10.1007","volume":"24","author":[{"given":"Vittorio","family":"Forestiero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Sconfienza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Mulatero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Monticone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"issue":"14","key":"9729_CR1","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","volume":"69","author":"S Monticone","year":"2017","unstructured":"Monticone S, Burrello J, Tizzani D, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69(14):1811\u201320.","journal-title":"J Am Coll Cardiol"},{"key":"9729_CR2","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1097\/HJH.0000000000002510","volume":"38","author":"P Mulatero","year":"2020","unstructured":"Mulatero P, Monticone S, Deinum J, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: A position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens. 2020;38:1919\u201328.","journal-title":"J Hypertens"},{"issue":"11","key":"9729_CR3","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293\u2013300.","journal-title":"J Am Coll Cardiol"},{"key":"9729_CR4","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","volume":"40","author":"DA Calhoun","year":"2002","unstructured":"Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892\u20136.","journal-title":"Hypertension"},{"issue":"9","key":"9729_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11906-020-01070-0","volume":"22","author":"A Agrawal","year":"2020","unstructured":"Agrawal A, Wenger NK. Hypertension during pregnancy. Curr Hypertens Rep. 2020;22(9):1\u20139.","journal-title":"Curr Hypertens Rep"},{"issue":"34","key":"9729_CR6","doi-asserted-by":"publisher","first-page":"31653241","DOI":"10.1093\/eurheartj\/ehy340","volume":"39","author":"V Regitz-Zagrosek","year":"2018","unstructured":"Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):31653241.","journal-title":"Eur Heart J"},{"issue":"11","key":"9729_CR7","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1161\/CIRCULATIONAHA.113.003904","volume":"129","author":"EW Seeley","year":"2014","unstructured":"Seeley EW, Ecker J. Chronic hypertension in pregnancy. Circulation. 2014;129(11):1254\u201361.","journal-title":"Circulation"},{"issue":"2","key":"9729_CR8","doi-asserted-by":"publisher","first-page":"134.e1","DOI":"10.1016\/j.ajog.2011.10.878","volume":"206","author":"BT Bateman","year":"2012","unstructured":"Bateman BT, Bansil P, Hernandez-Diaz S, et al. Prevalence, trends, and outcomes of chronic hypertension: A nationwide sample of delivery admissions. Am J Obstet Gynecol. 2012;206(2):134.e1-8.","journal-title":"Am J Obstet Gynecol"},{"key":"9729_CR9","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1161\/HYPERTENSIONAHA.119.12968","volume":"74","author":"CV Ananth","year":"2019","unstructured":"Ananth CV, Duzyj CM, Yadava S, et al. Changes in the prevalence of chronic hypertension in pregnancy, United States, 1970 to 2010. Hypertension. 2019;74:1089\u201395.","journal-title":"Hypertension"},{"issue":"6","key":"9729_CR10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/1471-0528.14918","volume":"125","author":"G Quartermaine","year":"2018","unstructured":"Quartermaine G. Hormone-secreting adrenal tumours cause severe hypertension and high rates of poor pregnancy outcome: A UK Obstetric Surveillance System study with case control comparisons. BJOG. 2018;125(6):719\u201327.","journal-title":"BJOG"},{"issue":"1","key":"9729_CR11","doi-asserted-by":"publisher","first-page":"R23","DOI":"10.1530\/EJE-14-0444","volume":"172","author":"A Riester","year":"2015","unstructured":"Riester A, Reincke M. Progress in primary aldosteronism: mineralcorticoid receptor antagonists and management of primary aldosteronism in pregnancy. Eur J Endocrinol \/ Eur Fed Endoc Soc. 2015;172(1):R23-30.","journal-title":"Eur J Endocrinol \/ Eur Fed Endoc Soc"},{"key":"9729_CR12","first-page":"200","volume":"23","author":"MG Crane","year":"1964","unstructured":"Crane MG, Andes JP, Harris JJ, et al. Primary aldosteronism in pregnancy. Obstet Gynecol. 1964;23:200\u20138.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"9729_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000506287","volume":"45","author":"T Zelinka","year":"2020","unstructured":"Zelinka T, Petrak O, Rosa J, et al. Primary aldosteronism and pregnancy. Kidney Blood Press Res. 2020;45(2):275\u201385.","journal-title":"Kidney Blood Press Res"},{"key":"9729_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.preghy.2021.06.005","volume":"25","author":"S Vidyasagar","year":"2021","unstructured":"Vidyasagar S, Kumar S, Morton A. Screening for primary aldosteronism in pregnancy. Pregnancy Hypertens. 2021;25:171\u20134.","journal-title":"Pregnancy Hypertens"},{"key":"9729_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/bjs.8976","volume":"100","author":"MA Biggar","year":"2013","unstructured":"Biggar MA, Lennard TW. Systematic review of phaeochromocytoma in pregnancy. Br J Surg. 2013;100:182\u201390.","journal-title":"Br J Surg"},{"issue":"2","key":"9729_CR16","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s12020-016-1117-0","volume":"55","author":"F Caimari","year":"2017","unstructured":"Caimari F, Valassi E, Garbayo P, et al. Cushing\u2019s syndrome and pregnancy outcomes: A systematic review of published cases. Endocrine. 2017;55(2):555\u201363.","journal-title":"Endocrine"},{"key":"9729_CR17","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: An endocrine society clinical practice guideline. Endocrinol Metab. 2016;101:1889\u2013916.","journal-title":"Endocrinol Metab"},{"issue":"9","key":"9729_CR18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1507\/endocrj.EJ11-0133","volume":"58","author":"T Nishikawa","year":"2011","unstructured":"Nishikawa T, Omura M, Satoh F, et al. Guidelines for the diagnosis and treatment of primary aldosteronism\u2013the Japan Endocrine Society 2009. Endocr J. 2011;58(9):711\u201321.","journal-title":"Endocr J"},{"issue":"3","key":"9729_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.7326\/M20-4873","volume":"174","author":"JB Cohen","year":"2021","unstructured":"Cohen JB, Cohen DL, Herman DS, et al. Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans. Ann Intern Med. 2021;174(3):289\u201397.","journal-title":"Ann Intern Med"},{"issue":"11","key":"9729_CR20","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1097\/HJH.0000000000001088","volume":"34","author":"P Mulatero","year":"2016","unstructured":"Mulatero P, Monticone S, Burrello J, et al. Guidelines for primary aldosteronism: Uptake by primary care physicians in Europe. J Hypertens. 2016;34(11):2253\u20137.","journal-title":"J Hypertens"},{"issue":"2","key":"9729_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ando.2016.04.009","volume":"77","author":"E Landau","year":"2016","unstructured":"Landau E, Amar L. Primary aldosteronism and pregnancy. Ann Endocrinol (Paris). 2016;77(2):148\u201360.","journal-title":"Ann Endocrinol (Paris)"},{"issue":"11","key":"9729_CR22","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrendo.2012.155","volume":"8","author":"S Monticone","year":"2012","unstructured":"Monticone S, Auchus RJ, Rainey WE. Adrenal disorders in pregnancy. Nat Rev Endocrinol. 2012;8(11):668\u201378.","journal-title":"Nat Rev Endocrinol"},{"key":"9729_CR23","first-page":"2067","volume":"149","author":"S Sch\u00fctz","year":"1996","unstructured":"Sch\u00fctz S, Le Moullec JM, Corvol P, et al. Early expression of all the components of the renin-angiotensin-system in human development. Am J Pathol. 1996;149:2067\u201379.","journal-title":"Am J Pathol"},{"issue":"9","key":"9729_CR24","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.placenta.2008.06.011","volume":"29","author":"RA Irani","year":"2008","unstructured":"Irani RA, Xia Y. The functional role of the renin-angiotensin system in pregnancy and preeclampsia. Placenta. 2008;29(9):763\u201371.","journal-title":"Placenta"},{"key":"9729_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/0002-9378(79)90789-0","volume":"134","author":"RC Franks","year":"1979","unstructured":"Franks RC, Hayashi RH. Maternal and fetal renin activity and renin and big renin concentrations in second-trimester pregnancy. Am J Obstet Gynecol. 1979;134:20\u20132.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"9729_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0002-9343(80)90178-3","volume":"68","author":"M Wilson","year":"1980","unstructured":"Wilson M, Morganti AA, Zervoudakis I, et al. Blood pressure, the renin-aldosterone system and sex steroids throughout normal pregnancy. Am J Med. 1980;68(1):97\u2013104.","journal-title":"Am J Med"},{"key":"9729_CR27","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/j.1471-0528.1973.tb02146.x","volume":"80","author":"BB Pirani","year":"1973","unstructured":"Pirani BB, Campbell DM, MacGillivray I. Plasma volume in normal first pregnancy. J Obstet Gynaecol Br Commonw. 1973;80:884\u20137.","journal-title":"J Obstet Gynaecol Br Commonw"},{"issue":"2","key":"9729_CR28","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1365-2265.2010.03901.x","volume":"74","author":"V Ronconi","year":"2011","unstructured":"Ronconi V, Turchi F, Zennaro MC, et al. Progesterone increase counteracts aldosterone action in a pregnant woman with primary aldosteronism. Clin Endocrinol (Oxf). 2011;74(2):278\u20139.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"9729_CR29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/ki.1980.133","volume":"18","author":"NF Gant","year":"1980","unstructured":"Gant NF, Worley RJ, Everett RB, et al. Control of vascular responsiveness during human pregnancy. Kidney Int. 1980;18(2):253\u20138.","journal-title":"Kidney Int"},{"issue":"4","key":"9729_CR30","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1210\/edrv-3-4-396","volume":"3","author":"ML Casey","year":"1982","unstructured":"Casey ML, MacDonald PC. Extraadrenal formation of a mineralocorticosteroid: Deoxycorticosterone and deoxycorticosterone sulfate biosynthesis and metabolism. Endocr Rev. 1982;3(4):396\u2013403.","journal-title":"Endocr Rev"},{"key":"9729_CR31","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1210\/jc.2005-1298","volume":"91","author":"K Saner-Amigh","year":"2006","unstructured":"Saner-Amigh K, Mayhew BA, Mantero F, et al. Elevated expression of luteinizing hormone receptor in aldosterone-producing adenomas. J Clin Endocrinol Metab. 2006;91:1136\u201342.","journal-title":"J Clin Endocrinol Metab"},{"key":"9729_CR32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1530\/EJE-08-0711","volume":"160","author":"O Zwermann","year":"2009","unstructured":"Zwermann O, Suttmann Y, Bidlingmaier M, et al. Screening for membrane hormone receptor expression in primary aldosteronism. Eur J Endocrinol. 2009;160:443\u201351.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"9729_CR33","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1530\/EJE-10-0879","volume":"164","author":"NM Albiger","year":"2011","unstructured":"Albiger NM, Sartorato P, Mariniello B, et al. A case of primary aldosteronism in pregnancy: Do LH and GNRH receptors have a potential role in regulating aldosterone secretion? Eur J Endocrinol. 2011;164(3):405\u201312.","journal-title":"Eur J Endocrinol"},{"issue":"15","key":"9729_CR34","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa1504869","volume":"373","author":"AED Teo","year":"2015","unstructured":"Teo AED, Garg S, Shaikh LH, et al. Pregnancy, primary aldosteronism, and adrenal CTNNB1 mutations. N Engl J Med. 2015;373(15):1429\u201336.","journal-title":"N Engl J Med"},{"issue":"8","key":"9729_CR35","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1210\/jc.2018-00087","volume":"103","author":"N Gagnon","year":"2018","unstructured":"Gagnon N. Genetic characterization of GnRH\/LH-responsive primary aldosteronism. J Clin Endocrinol Metab. 2018;103(8):2926\u201335.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"9729_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11906-020-01098-2","volume":"22","author":"P Gathiram","year":"2020","unstructured":"Gathiram P, Moodley J. The Role of the renin-angiotensin-aldosterone system in preeclampsia: A review. Curr Hypertens Rep. 2020;22(11):1\u20139.","journal-title":"Curr Hypertens Rep"},{"key":"9729_CR37","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1172\/JCI4106","volume":"103","author":"G Wallukat","year":"1999","unstructured":"Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest. 1999;103:945\u201352.","journal-title":"J Clin Invest"},{"issue":"2","key":"9729_CR38","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1161\/HYPERTENSIONAHA.109.140061","volume":"55","author":"AH Siddiqui","year":"2010","unstructured":"Siddiqui AH, Irani RA, Blackwell SC, et al. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: Correlation with disease severity. Hypertension. 2010;55(2):386\u201393.","journal-title":"Hypertension"},{"issue":"8","key":"9729_CR39","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/nm.1856","volume":"14","author":"CC Zhou","year":"2008","unstructured":"Zhou CC, Zhang Y, Irani RA, et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med. 2008;14(8):855\u201362.","journal-title":"Nat Med"},{"issue":"8","key":"9729_CR40","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1097\/HJH.0b013e328304dbff","volume":"26","author":"X Yang","year":"2008","unstructured":"Yang X, Wang F, Chang H, et al. Autoantibody against AT1 receptor from pre-eclamptic patients induces vasoconstriction through angiotensin receptor activation. J Hypertens. 2008;26(8):1629\u201335.","journal-title":"J Hypertens"},{"issue":"4","key":"9729_CR41","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1161\/HYPERTENSIONAHA.107.097790","volume":"51","author":"CC Zhou","year":"2008","unstructured":"Zhou CC, Ahmad S, Mi T, et al. Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin\/nuclear factor of activated T-cells signaling. Hypertension. 2008;51(4):1010\u20139.","journal-title":"Hypertension"},{"key":"9729_CR42","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1161\/HYPERTENSIONAHA.112.202945","volume":"61","author":"G Rossitto","year":"2013","unstructured":"Rossitto G, Regolisti G, Rossi E, et al. Elevation of angiotensin-II type-1-receptor autoantibodies titer in primary aldosteronism as a result of aldosterone-producing adenoma. Hypertension. 2013;61:526\u201333.","journal-title":"Hypertension"},{"key":"9729_CR43","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1210\/jc.2013-3282","volume":"99","author":"DC Kem","year":"2014","unstructured":"Kem DC, Li H, Velarde-Miranda C, et al. Autoimmune mechanisms activating the angiotensin AT1 receptor in primary aldosteronism. J Clin Endocrinol Metab. 2014;99:1790\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"9729_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jash.2014.10.009","volume":"9","author":"H Li","year":"2015","unstructured":"Li H, Yu X, Cicala MV, et al. Prevalence of angiotensin II type 1 receptor (AT1R)-activating autoantibodies in primary aldosteronism. J Am Soc Hypertens. 2015;9:15\u201320.","journal-title":"J Am Soc Hypertens"},{"key":"9729_CR45","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/jch.13351","volume":"20","author":"C Sabbadin","year":"2018","unstructured":"Sabbadin C, Ceccato F, Ragazzi E, et al. Evaluation of angiotensin II type-1 receptor antibodies in primary aldosteronism and further considerations about their possible pathogenetic role. J Clin Hypertens (Greenwich). 2018;20:1313\u20138.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"9729_CR46","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1161\/HYPERTENSIONAHA.119.13156","volume":"74","author":"TA Williams","year":"2019","unstructured":"Williams TA, Jaquin D, Burrello J, et al. Diverse responses of autoantibodies to the Angiotensin II type 1 receptor in primary aldosteronism. Hypertension. 2019;74:784\u201392.","journal-title":"Hypertension"},{"key":"9729_CR47","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1161\/HYPERTENSIONAHA.119.13388","volume":"74","author":"M Piazza","year":"2019","unstructured":"Piazza M, Seccia TM, Caroccia B, et al. AT1AA (Angiotensin II Type-1 Receptor Autoantibodies): Cause or Consequence of Human Primary Aldosteronism? Hypertension. 2019;74:793\u20139.","journal-title":"Hypertension"},{"issue":"11","key":"9729_CR48","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1210\/jcem-27-11-1628","volume":"27","author":"EG Biglieri","year":"1967","unstructured":"Biglieri EG, Slaton PE Jr. Pregnancy and primary aldosteronism. J Clin Endocrinol Metab. 1967;27(11):1628\u201332.","journal-title":"J Clin Endocrinol Metab"},{"key":"9729_CR49","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1536\/ihj.19.946","volume":"19","author":"W Aoi","year":"1978","unstructured":"Aoi W, Doi Y, Tasaki S, et al. Primary aldosteronism aggravated during peripartum period. Jpn Heart J. 1978;19:946\u201353.","journal-title":"Jpn Heart J"},{"issue":"9246","key":"9729_CR50","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1016\/S0140-6736(00)03311-0","volume":"356","author":"T Murakami","year":"2000","unstructured":"Murakami T, Ogura EW, Tanaka Y, et al. High blood pressure lowered by pregnancy. Lancet. 2000;356(9246):1980.","journal-title":"Lancet"},{"issue":"4","key":"9729_CR51","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/00000441-197410000-00005","volume":"268","author":"JF Aloia","year":"1974","unstructured":"Aloia JF, Beutow G. Malignant hypertension with aldosteronoma producing adenoma. Am J Med Sci. 1974;268(4):241\u20135.","journal-title":"Am J Med Sci"},{"issue":"3","key":"9729_CR52","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1067\/mob.2000.104229","volume":"182","author":"M Nezu","year":"2000","unstructured":"Nezu M, Miura Y, Noshiro T, et al. Primary aldosteronism as a cause of severe postpartum hypertension in two women. Am J Obstet Gynecol. 2000;182(3):745\u20136.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"9729_CR53","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1258\/om.2012.120012","volume":"6","author":"I Bretherton","year":"2013","unstructured":"Bretherton I, Pattison D, Pattison S, et al. An endocrine cause of acute post-partum hypertension. Obstet Med. 2013;6(1):30\u20132.","journal-title":"Obstet Med"},{"issue":"4","key":"9729_CR54","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1177\/1753495X18772999","volume":"12","author":"C Kilmartin","year":"2019","unstructured":"Kilmartin C, Opu T, Podymow T, et al. Primary hyperaldosteronism presenting as persistent postpartum hypertension: Illustrative case and systematic review. Obstet Med. 2019;12(4):190\u20135.","journal-title":"Obstet Med"},{"key":"9729_CR55","doi-asserted-by":"crossref","unstructured":"Ohara N, Kobayashi M, Yuichiro Y, et al. Primary aldosteronism presenting with hypertension five days after delivery: A case report and literature review. Intern Med 2021.","DOI":"10.2169\/internalmedicine.7778-21"},{"issue":"5","key":"9729_CR56","first-page":"838","volume":"56","author":"Y Hu","year":"2018","unstructured":"Hu Y, Ding Y, Yang M, et al. Serum prolactin levels across pregnancy and the establishment of reference intervals. Clin Chem Lab. 2018;56(5):838\u201342.","journal-title":"Clin Chem Lab"},{"issue":"9","key":"9729_CR57","doi-asserted-by":"publisher","first-page":"E1262","DOI":"10.1210\/JC.2015-2422","volume":"00","author":"TA Williams","year":"2015","unstructured":"Williams TA, Dietz AS, Theodoropoulou M, et al. Coexisting prolactinoma and primary aldosteronism: Is there a pathophysiological link? J Clin Endocrinol Metab. 2015;00(9):E1262\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"9729_CR58","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.preghy.2015.08.003","volume":"5","author":"A Morton","year":"2015","unstructured":"Morton A. Primary aldosteronism and pregnancy. Pregnancy Hypertens. 2015;5:259\u201362.","journal-title":"Pregnancy Hypertens"},{"key":"9729_CR59","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/AOG.0b013e3182075317","volume":"117","author":"L Mascetti","year":"2011","unstructured":"Mascetti L, Bettinelli A, Simonetti GD, et al. Pregnancy in inherited hypokalemic salt-losing renal tubular disorder. Obstet Gynecol. 2011;117:512\u20136.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"9729_CR60","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1161\/01.HYP.35.2.668","volume":"35","author":"JA Wyckoff","year":"2000","unstructured":"Wyckoff JA, Seely EW, Hurwitz S, et al. Glucocorticoid-remediable aldosteronism and pregnancy. Hypertension. 2000;35(2):668\u201372.","journal-title":"Hypertension"},{"issue":"1","key":"9729_CR61","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12020-021-02763-5","volume":"74","author":"V Sanga","year":"2021","unstructured":"Sanga V, Seccia TM, Rossi GP. A systematic review of pathophysiology and management of familial hyperaldosteronism type 1 in pregnancy. Endocrine. 2021;74(1):5\u201310.","journal-title":"Endocrine"},{"key":"9729_CR62","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1477-7827-11-76","volume":"11","author":"A Vecchiola","year":"2013","unstructured":"Vecchiola A, Lagos CF, Fuentes CA, et al. Different effects of progesterone and estradiol on chimeric and wild type aldosterone synthase in vitro. Reprod Biol Endocrinol. 2013;11:76.","journal-title":"Reprod Biol Endocrinol"},{"issue":"10","key":"9729_CR63","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1097\/HJH.0000000000002520","volume":"38","author":"P Mulatero","year":"2020","unstructured":"Mulatero P, Sechi LA, Williams TA, et al. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: A position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020;38(10):1929\u201336.","journal-title":"J Hypertens"},{"issue":"7","key":"9729_CR64","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11906-015-0563-z","volume":"17","author":"L Malha","year":"2015","unstructured":"Malha L, August P. Secondary hypertension in pregnancy. Curr Hypertens Rep. 2015;17(7):53.","journal-title":"Curr Hypertens Rep"},{"key":"9729_CR65","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ecl.2015.02.006","volume":"44","author":"DC Eschler","year":"2015","unstructured":"Eschler DC, Kogekar N, Pessah-Pollack R. Management of adrenal tumors in pregnancy. Endocrinol Metab Clin North Am. 2015;44:381\u201397.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"9729_CR66","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1159\/000507116","volume":"45","author":"GB Piccoli","year":"2020","unstructured":"Piccoli GB, Mannucci C. Preeclampsia: A diagnosis-nondiagnosis that is too easily made: The case of primary hyperaldosteronism. Kidney Blood Press Res. 2020;45:363\u20137.","journal-title":"Kidney Blood Press Res"},{"issue":"2","key":"9729_CR67","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1161\/HYPERTENSIONAHA.118.10854","volume":"72","author":"L Malha","year":"2018","unstructured":"Malha L, Sison CP, Helseth G, et al. Renin-Angiotensin-Aldosterone profiles in pregnant women with chronic hypertension. Hypertension. 2018;72(2):417\u201324.","journal-title":"Hypertension"},{"issue":"1","key":"9729_CR68","doi-asserted-by":"publisher","first-page":"69","DOI":"10.21037\/gs.2019.12.04","volume":"9","author":"AH Affinati","year":"2020","unstructured":"Affinati AH, Auchus RJ. Endocrine causes of hypertension in pregnancy. Gland Surg. 2020;9(1):69\u201379.","journal-title":"Gland Surg"},{"issue":"24","key":"9729_CR69","first-page":"2367","volume":"372","author":"LA Magee","year":"2015","unstructured":"Magee LA, Singer J, Von Dadelszen P, CHIPS Study Group. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(24):2367\u20138.","journal-title":"N Engl J Med"},{"key":"9729_CR70","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1161\/HYPERTENSIONAHA.117.10803","volume":"72","author":"MA Brown","year":"2018","unstructured":"Brown MA, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72:24\u201343.","journal-title":"Hypertension"},{"key":"9729_CR71","unstructured":"Chronic Hypertension and Pregnancy (CHAP) Project (CHAP). Ongoing clinical trial. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02299414. Accessed 9 Feb 2022"},{"key":"9729_CR72","first-page":"540","volume":"95","author":"A Hecker","year":"1980","unstructured":"Hecker A, Hasan SH, Neumann F. Disturbances in sexual differentiation of rat foetuses following spironolactone treatment. Acta Endocrinol. 1980;95:540\u20135.","journal-title":"Acta Endocrinol"},{"issue":"4","key":"9729_CR73","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.jaad.2018.10.023","volume":"80","author":"W Liszewski","year":"2019","unstructured":"Liszewski W, Boull C. Lack of evidence for feminization of males exposed to spironolactone in utero: A systematic review. J Am Acad Dermatol. 2019;80(4):1147\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"9729_CR74","doi-asserted-by":"crossref","unstructured":"Shah A. Ambiguous genitalia in a newborn with spironolactone exposure. In 93rd Annual Meeting of the Endocrine Society Boston. 2011. (Vol. 6).","DOI":"10.1210\/endo-meetings.2011.PART3.P27.P3-227"},{"issue":"5","key":"9729_CR75","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/0002-9378(95)90549-9","volume":"172","author":"TD Groves","year":"1995","unstructured":"Groves TD, Corenblum B. Spironolactone therapy during human pregnancy. Am J Obstet Gynecol. 1995;172(5):1655\u20136.","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"9729_CR76","first-page":"421","volume":"77","author":"Z Rusavy","year":"2012","unstructured":"Rusavy Z, Hudec A, Karbanova J, et al. Gitelman syndrome in pregnancy \u2013 a severe hypokalemia with favorable perinatal prognosis. Ceska Ginecol. 2012;77(5):421\u20133.","journal-title":"Ceska Ginecol"},{"issue":"1","key":"9729_CR77","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s12884-020-03117-1","volume":"20","author":"M Kersten","year":"2020","unstructured":"Kersten M, Hancke K, Janni W, et al. Pregnancy induced Cushing\u2019s syndrome and primary aldosteronism: A case report. BMC Pregnancy Childbirth. 2020;20(1):421.","journal-title":"BMC Pregnancy Childbirth"},{"issue":"4","key":"9729_CR78","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/clc.20324","volume":"31","author":"A Struthers","year":"2008","unstructured":"Struthers A, Krum H, Williams GHA. comparison of aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 2008;31(4):153\u20138.","journal-title":"Clin Cardiol"},{"key":"9729_CR79","unstructured":"FDA Report of Eplerenone. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021437s006lbl.pdf. 2008. Accessed 9 Feb 2022"},{"issue":"3","key":"9729_CR80","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1527-5299.2005.05316.x","volume":"12","author":"DA Hutter","year":"2006","unstructured":"Hutter DA, Berkowitz R, Davis SE, et al. Application of continuous positive airway pressure in hypoxemic acute respiratory failure associated with diastolic dysfunction in pregnancy. Congest Heart Fail. 2006;12(3):174\u20135.","journal-title":"Congest Heart Fail"},{"issue":"3","key":"9729_CR81","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1440-1797.2010.01396.x","volume":"16","author":"A Morton","year":"2011","unstructured":"Morton A, Panitz B, Bush A. Eplerenone for Gitelman syndrome in pregnancy. Nephrology (Carlton). 2011;16(3):349.","journal-title":"Nephrology (Carlton)"},{"issue":"2","key":"9729_CR82","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1161\/HYPERTENSIONAHA.111.187237","volume":"59","author":"A Cabassi","year":"2012","unstructured":"Cabassi A, Rocco R, Berretta R, et al. Eplerenone use in primary aldosteronism during pregnancy. Hypertension. 2012;59(2):e18\u20139.","journal-title":"Hypertension"},{"issue":"1","key":"9729_CR83","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ccr3.355","volume":"4","author":"K Gunganah","year":"2016","unstructured":"Gunganah K, Carpenter R, Drake WM. Eplerenone use in primary aldosteronism during pregnancy. Clinical Case Reports. 2016;4(1):81\u20138.","journal-title":"Clinical Case Reports"},{"key":"9729_CR84","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.preghy.2016.12.001","volume":"7","author":"A Morton","year":"2017","unstructured":"Morton A, Laurie J. Eplerenone in the management of resistant hypertension with obstructive sleep apnoea in pregnancy. Pregnancy Hypertens. 2017;7:54\u20135.","journal-title":"Pregnancy Hypertens"},{"issue":"1","key":"9729_CR85","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/1753495X19825967","volume":"14","author":"J Gehlert","year":"2021","unstructured":"Gehlert J, Morton A. Eplerenone as a treatment for resistant hypertension in pregnancy. Obstet Med. 2021;14(1):35\u20138.","journal-title":"Obstet Med"},{"key":"9729_CR86","unstructured":"FDA Report of Amiloride. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2002\/18-200S024_Midamor_Prntlbl.pdf. 2002. Accessed 9 Feb 2022"},{"issue":"7","key":"9729_CR87","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1080\/01443610701667098","volume":"27","author":"NA Al-Ali","year":"2007","unstructured":"Al-Ali NA, El-Sandabesee D, Steel SA, et al. Conn\u2019s syndrome in pregnancy successfully treated with amiloride. J Obstet Gynaecol. 2007;27(7):730\u20131.","journal-title":"J Obstet Gynaecol"},{"key":"9729_CR88","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1089\/lap.2000.10.169","volume":"10","author":"AL Shalhav","year":"2000","unstructured":"Shalhav AL, Landman J, Afane J, et al. Laparoscopic adrenalectomy for primary hyperaldosteronism during pregnancy. J Laparoendosc Adv Surg Tech A. 2000;10:169\u201371.","journal-title":"J Laparoendosc Adv Surg Tech A"},{"key":"9729_CR89","first-page":"130","volume":"67","author":"R Krysiak","year":"2012","unstructured":"Krysiak R, Samborek M, Stojko R. Primary aldosteronism in pregnancy. Acta Clin Belg. 2012;67:130\u20134.","journal-title":"Acta Clin Belg"},{"key":"9729_CR90","doi-asserted-by":"crossref","unstructured":"Ghela A, Kashif M, Akhtar A, et al. A challenging case of primary aldosteronism presenting in pregnancy. In Endocrine Abstracts. 2017;50.","DOI":"10.1530\/endoabs.50.EP003"},{"key":"9729_CR91","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1161\/HYPERTENSIONAHA.121.17021","volume":"78","author":"S Kulkarni","year":"2021","unstructured":"Kulkarni S, Dominiczak AF, Touyz RM, et al. CONNed in pregnancy. Hypertension. 2021;78:241\u20139.","journal-title":"Hypertension"},{"issue":"4","key":"9729_CR92","first-page":"200043","volume":"2020","author":"S Shekhar","year":"2020","unstructured":"Shekhar S, Haykal R, Kamilaris C, et al. Curative resection of an aldosteronoma causing primary aldosteronism in the second trimester of pregnancy. Endocrinol Diabetes Metab Case Rep. 2020;2020(4):200043.","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"3","key":"9729_CR93","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1210\/jcem-27-3-385","volume":"27","author":"RD Gordon","year":"1967","unstructured":"Gordon RD, Fishman LM, Liddle GW. Plasma renin activity and aldosterone secretion in a pregnant woman with primary aldosteronism. J Clin Endocrinol Metab. 1967;27(3):385\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4 Pt 2","key":"9729_CR94","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/0029-7844(95)00208-9","volume":"86","author":"F Baron","year":"1995","unstructured":"Baron F, Sprauve ME, Huddleston JF. Diagnostic and surgical treatment of primary aldosteronism in pregnancy: A case report. Obstet Gynecol. 1995;86(4 Pt 2):644\u20135.","journal-title":"Obstet Gynecol"},{"issue":"4","key":"9729_CR95","first-page":"279","volume":"164","author":"E Aboud","year":"1995","unstructured":"Aboud E, De Swiet M, Gorton H. Primary aldosteronism in pregnancy: Should it be treated surgically? J Med Sci. 1995;164(4):279\u201380.","journal-title":"J Med Sci"},{"key":"9729_CR96","first-page":"255","volume":"41","author":"CG Solomon","year":"1996","unstructured":"Solomon CG, Thiet M, Moore FJ, et al. Primary hyperaldosteronism in pregnancy. A case report. J Reprod Med. 1996;41:255\u20138.","journal-title":"J Reprod Med"},{"key":"9729_CR97","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1507\/endocrj.K05-122","volume":"53","author":"K Kosaka","year":"2006","unstructured":"Kosaka K, Onoda N, Ishikawa T, et al. Laparoscopic adrenalectomy on a patient with primary aldosteronism during pregnancy. Endocr J. 2006;53:461\u20136.","journal-title":"Endocr J"},{"key":"9729_CR98","first-page":"E188","volume":"52","author":"TZ Nursal","year":"2009","unstructured":"Nursal TZ, Caliskan K, Ertorer E, et al. Laparoscopic treatment of primary hyperaldosteronism in a pregnant patient. Can J Surg. 2009;52:E188\u201390.","journal-title":"Can J Surg"},{"key":"9729_CR99","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s12022-009-9060-8","volume":"20","author":"K Shigematsu","year":"2009","unstructured":"Shigematsu K, Nishida N, Sakai H, et al. Primary aldosteronism with aldosterone-producing adenoma consisting of pure zona glomerulosa-type cells in a pregnant woman. Endocr Pathol. 2009;20:66\u201372.","journal-title":"Endocr Pathol"},{"issue":"8","key":"9729_CR100","first-page":"381","volume":"60","author":"K Shirashi","year":"2014","unstructured":"Shirashi K, Kikuta K, Nitta Y, et al. Laparoscopic adrenalectomy due to primary aldosteronism during pregnancy. Hinyokika Kiyo. 2014;60(8):381\u20135.","journal-title":"Hinyokika Kiyo"},{"key":"9729_CR101","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1210\/jc.2012-2234","volume":"97","author":"E Fischer","year":"2012","unstructured":"Fischer E, Hanslik G, Pallauf A, et al. Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism after adrenalectomy. J Clin Endocrinol Metab. 2012;97:3965\u201373.","journal-title":"J Clin Endocrinol Metab"},{"key":"9729_CR102","first-page":"21","volume":"2021","author":"LM Angus","year":"2021","unstructured":"Angus LM, Yang J, Cheung AS. Persistent hypoaldosteronism post-adrenalectomy for primary aldosteronism - a role for pre-operative spironolactone? Endocrinol Diabetes Metab Case Rep. 2021;2021:21\u20130137.","journal-title":"Endocrinol Diabetes Metab Case Rep"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-022-09729-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-022-09729-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-022-09729-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T14:16:04Z","timestamp":1675520164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-022-09729-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,10]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["9729"],"URL":"https:\/\/doi.org\/10.1007\/s11154-022-09729-6","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,10]]},"assertion":[{"value":"20 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Funding information has been added in the Funding Note.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"P.M. received fees from DiaSorin for educational speeches.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}